Kyri K. Van Hoose - Jan 3, 2022 Form 4 Insider Report for Dermata Therapeutics, Inc. (DRMA)

Role
SVP, Chief Financial Officer
Signature
/s/ Gerald T. Proehl, Attorney-in-Fact
Stock symbol
DRMA
Transactions as of
Jan 3, 2022
Transactions value $
$0
Form type
4
Date filed
1/5/2022, 06:15 PM
Previous filing
Sep 1, 2021
Next filing
Jan 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DRMA Stock Option (right to buy) Award $0 +30K $0.00 30K Jan 3, 2022 Common Stock 30K $1.88 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest as to 40% upon the 12 month anniversary of the grant date, and will vest as to 60% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date.